Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1470988
This article is part of the Research Topic Exploring Novel Targets and Therapies to Combat Antimicrobial Resistance View all articles

Screening canine sources for novel antimicrobials reveals the circular broad-spectrum bacteriocin, caledonicin produced by Staphylococcus caledonicus

Provisionally accepted
  • 1 School of Microbiology, University College Cork, Cork, Ireland
  • 2 APC Microbiome Institute, College of Medicine and Health, University College Cork, Cork, Ireland
  • 3 Moorepark Food Research Centre, Teagasc Food Research Centre (Ireland), Fermoy, Ireland

The final, formatted version of the article will be published soon.

    Antimicrobial-resistant pathogens present an ongoing threat to human and animal health, with deaths linked to antimicrobial resistance (AMR) predicted to increase yearly. While the misuse and overuse of antibiotics in humans undoubtedly contribute to this escalation, antibiotic use in the veterinary field, including companion animals, also plays a contributing role. Pet owners' desire to improve the quality of life of their pets is likely to support antibiotic use within this field. Consequently, there is a need for antibiotic alternatives to treat bacterial infections. This study set out to screen for antimicrobial peptides known as bacteriocins from bacterial isolates of aerobic/microaerophilic environments of canine sources and determine their potential as antibiotic alternatives against clinically relevant pathogens. Following a laboratory-based protocol, 22 bacterial isolates were subjected to whole genome sequencing (WGS) and a total of 14 putative novel bacteriocins were identified from both class I and II bacteriocin classes.One particular bacteriocin, herein named caledonicin, was identified via in silico analysis from a Staphylococcus caledonicus strain, and partially purified for further in vitro evaluation. Caledonicin is a 64 amino acid (IAANLGVSSGTAYSMANALNNISNVATALTIIGTFTGVGTIGSGIAATILAILKKKGV AAAAAF) novel circular bacteriocin most closely related to enterocin_NKR-5-3B based on core peptide alignment (39.1%), with a molecular weight of 6077.1 Da. Caledonicin exhibits a broad spectrum of activity against a range of pathogenic bacteria, including methicillinresistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus pseudintermedius (MRSP), and Listeria monocytogenes; and the gut related bacterium associated with Crohn's disease, Mediterraneibacter gnavus ATCC 29149 (previously Ruminococcus gnavus ATCC 29149). This represents the first bacteriocin screening study involving bacteria from canine sources and confirms this is a rich environment for bacteriocinproducing strains. This study also identifies and characterises the first novel bacteriocin from the staphylococcal species, Staphylococcus caledonicus.

    Keywords: antimicrobial resistance, canine microbiota, Bacteriocins, canine sources, Antimicrobial potential, antimicrobial peptides

    Received: 26 Jul 2024; Accepted: 06 Aug 2024.

    Copyright: © 2024 O'Connor, O'Connor, Hourigan, De Farias, Field, Hill and Ross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Paul Ross, APC Microbiome Institute, College of Medicine and Health, University College Cork, Cork, Ireland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.